应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BBIO BridgeBio Pharma, Inc.
盘后交易 04-17 16:58:33 EDT
24.98
-0.26
-1.03%
盘后
25.39
+0.41
+1.64%
16:08 EDT
最高
25.66
最低
24.80
成交量
172.27万
今开
25.54
昨收
25.24
日振幅
3.41%
总市值
46.08亿
流通市值
29.62亿
总股本
1.84亿
成交额
4,335万
换手率
1.45%
流通股本
1.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Bridgebio Pharma, Inc.盘中异动 下午盘急速上涨5.01%报28.70美元
自选股智能写手 · 04-12
Bridgebio Pharma, Inc.盘中异动 下午盘急速上涨5.01%报28.70美元
Bridgebio Pharma, Inc.盘中异动 下午盘大幅下跌5.08%报26.98美元
自选股智能写手 · 04-11
Bridgebio Pharma, Inc.盘中异动 下午盘大幅下跌5.08%报26.98美元
Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%
自选股智能写手 · 03-21
Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%
美国研究综述-迪克体育用品、Nvidia、PVH
Reuters · 03-20
美国研究综述-迪克体育用品、Nvidia、PVH
美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co
Reuters · 03-07
美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co
Bridgebio Pharma, Inc.盘中异动 急速跳水5.02%报30.73美元
自选股智能写手 · 03-05
Bridgebio Pharma, Inc.盘中异动 急速跳水5.02%报30.73美元
美国研究综述-CommScope Holding Company、Dutch Bros、Hess
Reuters · 03-05
美国研究综述-CommScope Holding Company、Dutch Bros、Hess
Bridgebio Pharma, Inc.盘中异动 早盘股价大跌5.05%
自选股智能写手 · 03-04
Bridgebio Pharma, Inc.盘中异动 早盘股价大跌5.05%
BUZZ-BridgeBio 因与拜耳达成心脏病药物许可协议而上涨
Reuters · 03-04
BUZZ-BridgeBio 因与拜耳达成心脏病药物许可协议而上涨
BridgeBio Pharma Inc 报告截至 12 月的季度业绩 - 收益摘要
Reuters · 02-23
BridgeBio Pharma Inc 报告截至 12 月的季度业绩 - 收益摘要
Bridgebio Pharma Inc盘中异动 股价大跌5.21%报35.27美元
自选股智能写手 · 02-21
Bridgebio Pharma Inc盘中异动 股价大跌5.21%报35.27美元
Bridgebio Pharma Inc盘中异动 急速跳水5.02%报37.26美元
自选股智能写手 · 02-17
Bridgebio Pharma Inc盘中异动 急速跳水5.02%报37.26美元
BUZZ-竞争对手 Alnylam 更改心脏病药物研究目标后,BridgeBio 公司业绩上升
Reuters · 02-16
BUZZ-竞争对手 Alnylam 更改心脏病药物研究目标后,BridgeBio 公司业绩上升
加载更多
公司概况
公司名称:
BridgeBio Pharma, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
BridgeBio Pharma, Inc.于2019年5月17日成立为特拉华州公司。他们是一个由经验丰富的药物发现者,开发者和创新者组成的团队,致力于创造改变生命的药物,从源头上瞄准特征明确的遗传性疾病。他们确定和推进转化药物治疗患有孟德尔疾病的患者,这些疾病是由单一基因缺陷引起的疾病,以及具有明确遗传驱动因素的癌症。
发行价格:
--
{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":24.98,"timestamp":1713384000000,"preClose":25.24,"halted":0,"volume":1722654,"hourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":24.98,"latestTime":"16:08 EDT","volume":65691,"amount":1640961.508455,"timestamp":1713384499887},"delay":0,"floatShares":118565337,"shares":184452226,"eps":-3.951078,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.26,"latestTime":"04-17 16:58:33 EDT","open":25.54,"high":25.66,"low":24.8,"amount":43346808.407124,"amplitude":0.034073,"askPrice":25.48,"askSize":58,"bidPrice":24.52,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.951078,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1713398400000},"adr":0,"listingDate":1561608000000,"adjPreClose":25.24,"preHourTrading":{"tag":"盘前","latestPrice":25.5,"preClose":25.24,"latestTime":"09:29 EDT","volume":360,"amount":9154.64988,"timestamp":1713360599999},"postHourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":24.98,"latestTime":"16:08 EDT","volume":65691,"amount":1640961.508455,"timestamp":1713384499887},"volumeRatio":1.068858},"requestUrl":"/m/hq/s/BBIO","defaultTab":"news","newsList":[{"id":"2426299354","title":"Bridgebio Pharma, Inc.盘中异动 下午盘急速上涨5.01%报28.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426299354","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426299354?lang=zh_cn&edition=full","pubTime":"2024-04-12 02:17","pubTimestamp":1712859445,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日02时17分,Bridgebio Pharma, Inc.股票出现异动,股价快速拉升5.01%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.05%。其相关个股中,Rallybio Corporation、Eliem Therapeutics, Inc、Candel Therapeutics, Inc.涨幅较大,Adial Pharmaceuticals, Inc、Aptevo Therapeutics Inc.、Scisparc Ltd.较为活跃,换手率分别为812.12%、614.74%、516.20%,振幅较大的相关个股有Veru Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Rallybio Corporation,振幅分别为53.23%、52.42%、50.92%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041202172587e7faef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041202172587e7faef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426487254","title":"Bridgebio Pharma, Inc.盘中异动 下午盘大幅下跌5.08%报26.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426487254","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426487254?lang=zh_cn&edition=full","pubTime":"2024-04-11 01:07","pubTimestamp":1712768847,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日01时07分,Bridgebio Pharma, Inc.股票出现波动,股价急速跳水5.08%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为1.23%。其相关个股中,Adial Pharmaceuticals, Inc、Jaguar Health, Inc.、Clene Inc C/Wts 30/12/2025 涨幅较大,Adial Pharmaceuticals, Inc、Silo Pharma, Inc.、Jaguar Health, Inc.较为活跃,换手率分别为1946.31%、76.78%、53.12%,振幅较大的相关个股有Adial Pharmaceuticals, Inc、Orgenesis Inc.、Nutriband Inc C/Wts ,振幅分别为87.61%、74.23%、52.44%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110107287a51ed76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110107287a51ed76&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421045058","title":"Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421045058","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421045058?lang=zh_cn&edition=full","pubTime":"2024-03-21 21:45","pubTimestamp":1711028743,"startTime":"0","endTime":"0","summary":"北京时间2024年03月21日21时45分,Bridgebio Pharma, Inc.股票出现异动,股价快速拉升5.03%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。消息层面,截至21时45分,Bridgebio Pharma, Inc.股票正面舆情新闻比例100%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321214543791c0695&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321214543791c0695&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420798966","title":"美国研究综述-迪克体育用品、Nvidia、PVH","url":"https://stock-news.laohu8.com/highlight/detail?id=2420798966","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420798966?lang=zh_cn&edition=full","pubTime":"2024-03-20 15:14","pubTimestamp":1710918896,"startTime":"0","endTime":"0","summary":" 路透社3月20日 - 华尔街证券分析师周三调整了对迪克体育用品公司、英伟达和 PVH 等几家美国上市公司的评级和目标价。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417781874","title":"美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2417781874","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417781874?lang=zh_cn&edition=full","pubTime":"2024-03-07 14:49","pubTimestamp":1709794169,"startTime":"0","endTime":"0","summary":" 路透社3月7日 - 华尔街证券分析师周四修改了对几家美国上市公司的评级和目标价,其中包括 Highpeak Energy、Nordstrom 和 Victoria'S Secret & Co。公司要闻 * Highpeak Energy Inc :Gerdes Energy Research将其评级从买入下调至卖出 * Nordstrom Inc :杰富瑞将其评级从买入下调至持有 * 维多利亚的秘密 :摩根大通将其股票评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417414969","title":"Bridgebio Pharma, Inc.盘中异动 急速跳水5.02%报30.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417414969","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417414969?lang=zh_cn&edition=full","pubTime":"2024-03-05 22:34","pubTimestamp":1709649261,"startTime":"0","endTime":"0","summary":"北京时间2024年03月05日22时34分,Bridgebio Pharma, Inc.股票出现波动,股价大幅下跌5.02%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.28%。其相关个股中,Apogee Therapeutics, Inc.、Jasper Therapeutics Inc C/Wts 24/09/2026 、Ys Biopharma Co Ltd C/Wts 15/03/2028 涨幅较大,Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.、CASI制药较为活跃,换手率分别为205.47%、92.43%、45.68%,振幅较大的相关个股有Ocean Biomedical Inc C/Wts 14/02/2028 、Ocean Biomedical, Inc.、Eyenovia, Inc.,振幅分别为25.10%、17.89%、17.54%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030522342287e76184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030522342287e76184&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417176870","title":"美国研究综述-CommScope Holding Company、Dutch Bros、Hess","url":"https://stock-news.laohu8.com/highlight/detail?id=2417176870","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417176870?lang=zh_cn&edition=full","pubTime":"2024-03-05 03:21","pubTimestamp":1709580103,"startTime":"0","endTime":"0","summary":" 路透社3月4日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价,其中包括 CommScope Holding Company、Dutch Bros 和 Hess。要点 * CommScope Holding Company :摩根大通将其股票评级从中性下调至减持 * 荷兰兄弟 :Piper Sandler 将其评级从中性上调至增持 * Hess Corp :Susquehanna 将目标价从 152 美元上调至 156 美元 * Pioneer Natural Resources Co :苏斯克汉纳将目标价从237美元上调至246美元 * United Therapeutics Corp :摩根大通将目标价从294美元下调至280美元 以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416142992","title":"Bridgebio Pharma, Inc.盘中异动 早盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416142992","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416142992?lang=zh_cn&edition=full","pubTime":"2024-03-04 22:43","pubTimestamp":1709563437,"startTime":"0","endTime":"0","summary":"北京时间2024年03月04日22时43分,Bridgebio Pharma, Inc.股票出现异动,股价急速跳水5.05%。Bridgebio Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.51%。其相关个股中,Quoin Pharmaceuticals Ltd、Tc Biopharm Plc C/Wts 10/02/2028 、Jaguar Health, Inc.涨幅较大,Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.、Adial Pharmaceuticals, Inc较为活跃,换手率分别为1392.03%、192.88%、75.53%,振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.,振幅分别为63.43%、50.90%、27.12%。Bridgebio Pharma, Inc.公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030422435787e75ae8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030422435787e75ae8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416114115","title":"BUZZ-BridgeBio 因与拜耳达成心脏病药物许可协议而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2416114115","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2416114115?lang=zh_cn&edition=full","pubTime":"2024-03-04 20:11","pubTimestamp":1709554311,"startTime":"0","endTime":"0","summary":" 3月4日 - ** BridgeBio Pharma 股价盘前上涨1%至36.0美元** 该公司表示, ,它已与德国制药商拜耳 达成了在欧洲商业化其心脏病药物的许可协议** 该药名为acoramidis,是一种治疗转甲状腺素淀粉样变性心肌病的口服药物。** 根据交易,BBIO 将获得高达 3.1 亿美元的收益,包括前期和里程碑付款 - BBIO** Says 还将获得分级版税,从阿可拉米地斯在欧洲销售额的 30% 开始 -BBIO** TD COwen 分析师 Tyler Van Buren 在一份说明中写道:\"这是一笔可靠的交易,而且鉴于年底前可能获得批准,时机非常合适。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413825204","title":"BridgeBio Pharma Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2413825204","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413825204?lang=zh_cn&edition=full","pubTime":"2024-02-23 11:02","pubTimestamp":1708657325,"startTime":"0","endTime":"0","summary":" * BridgeBio Pharma Inc 报告了截至12月底的季度调整后每股亏损96美分,低于去年同期的每股收益-92美分。华尔街预期为每股亏损 1.16 美元至-72 美分。* 营收同比下降 6.7% 至 175 万美元,分析师预期为 623 万美元。* BridgeBio Pharma 公司公布的本季度每股收益为亏损 96 美分。* 该公司当季亏损 1.6815 亿美元。* BridgeBio Pharma Inc 本季度股价下跌了 15.4%。2月23日 - 预测变化 * 在过去三个月中,分析师的平均盈利预测上升了约 1.1%。华尔街对 BridgeBio Pharma Inc 的 12 个月目标价中位数为 50.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413648394","title":"Bridgebio Pharma Inc盘中异动 股价大跌5.21%报35.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413648394","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413648394?lang=zh_cn&edition=full","pubTime":"2024-02-21 01:37","pubTimestamp":1708450635,"startTime":"0","endTime":"0","summary":"北京时间2024年02月21日01时37分,Bridgebio Pharma Inc股票出现波动,股价大幅下挫5.21%。Bridgebio Pharma Inc股票所在的生物技术行业中,整体跌幅为0.90%。其相关个股中,60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Monopar Therapeutics Inc涨幅较大,Scisparc Ltd、Monopar Therapeutics Inc、Clearmind Medicine Inc较为活跃,换手率分别为2552.97%、602.29%、343.49%,振幅较大的相关个股有Sab Biotherapeutics Inc C/Wts 22/10/2026 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Monopar Therapeutics Inc,振幅分别为1060.57%、333.33%、233.51%。Bridgebio Pharma Inc公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402210137157912cbec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402210137157912cbec&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2412696674","title":"Bridgebio Pharma Inc盘中异动 急速跳水5.02%报37.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2412696674","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2412696674?lang=zh_cn&edition=full","pubTime":"2024-02-17 01:58","pubTimestamp":1708106302,"startTime":"0","endTime":"0","summary":"北京时间2024年02月17日01时58分,Bridgebio Pharma Inc股票出现异动,股价大幅跳水5.02%。Bridgebio Pharma Inc公司简介:BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物,以及具有明确基因驱动因素的癌症。消息层面,截至01时58分,Bridgebio Pharma Inc股票正面舆情新闻比例50%。《BridgeBio Pharma董事增持3,433股普通股股份,价值约4.45万美元》资讯为影响Bridgebio Pharma Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217015822861d5938&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217015822861d5938&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411252722","title":"BUZZ-竞争对手 Alnylam 更改心脏病药物研究目标后,BridgeBio 公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2411252722","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411252722?lang=zh_cn&edition=full","pubTime":"2024-02-16 03:34","pubTimestamp":1708025681,"startTime":"0","endTime":"0","summary":" 2月15日 - ** 制药商Bridgebio Pharma 股价上涨19.4%,至41.01美元 ** 如果涨势得以保持,股价将创7个多月来最大单日涨幅 ** Alnylam 修改了 关键目标,以测试其药物Amvuttra作为ATTR淀粉样变性相关心肌病的治疗方法。** BBIO正在开发一种名为acoramidis的药物,用于治疗同一种疾病,目前正处于后期试验阶段。** 瑞穗证券公司表示:\"除非公司觉得有必要,否则不会随便改变统计计划。** 股价在过去 12 个月中增长了两倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bridgebio.com","stockEarnings":[{"period":"1week","weight":-0.1122},{"period":"1month","weight":-0.0842},{"period":"3month","weight":-0.3162},{"period":"6month","weight":0.0227},{"period":"1year","weight":0.6793},{"period":"ytd","weight":-0.3748}],"compareEarnings":[{"period":"1week","weight":-0.0304},{"period":"1month","weight":-0.0124},{"period":"3month","weight":0.0661},{"period":"6month","weight":0.1808},{"period":"1year","weight":0.2164},{"period":"ytd","weight":0.0594}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日成立为特拉华州公司。他们是一个由经验丰富的药物发现者,开发者和创新者组成的团队,致力于创造改变生命的药物,从源头上瞄准特征明确的遗传性疾病。他们确定和推进转化药物治疗患有孟德尔疾病的患者,这些疾病是由单一基因缺陷引起的疾病,以及具有明确遗传驱动因素的癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.111762},{"month":2,"riseRate":0.4,"avgChangeRate":0.037273},{"month":3,"riseRate":0.4,"avgChangeRate":0.087947},{"month":4,"riseRate":0.2,"avgChangeRate":-0.111449},{"month":5,"riseRate":0.25,"avgChangeRate":-0.046032},{"month":6,"riseRate":1,"avgChangeRate":0.181159},{"month":7,"riseRate":0.4,"avgChangeRate":0.163437},{"month":8,"riseRate":0.6,"avgChangeRate":0.020787},{"month":9,"riseRate":0.2,"avgChangeRate":-0.055084},{"month":10,"riseRate":0.8,"avgChangeRate":0.03327},{"month":11,"riseRate":0.6,"avgChangeRate":0.082541},{"month":12,"riseRate":0.6,"avgChangeRate":0.051049}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}